Covid19 National Telangana

In 2021, Hyderabad will emerge as a global hub for Covid 19 vaccines

Hyderabad: As the world prepares for a new year amid covid-19 epidemics, the city is likely to emerge as a ‘savior’ from the deadly virus, with more than five vaccine companies based here bringing in an antidote. Vaccine development by Bharat Biotech, Biological E Ltd and Aurobindo Pharma is currently in various stages, while Dr Reddy and Heathrow have signed an agreement to develop the vaccine.

Some of these companies have also drawn up plans to increase their vaccine manufacturing capabilities.

Apart from vaccine manufacturers, the international airport here has also extended cold-chain infrastructure for vaccine transport.

GMR Hyderabad Air Cargo (GHAC) covid-19 is negotiating with various stakeholders towards meeting specific requirements of export and import of vaccines.

The recent visit of more than 60 envoys to the vaccine manufacturing facilities of Bharat Biotech and BE establishes the fact that the city will be at the forefront of manufacturing and supplying vaccines for covid-19

which will provide more than 77 million cases to the world and almost two million deaths.

Except India Biotech, all these vaccine manufacturers are developing or manufacturing tie ups with foreign companies

Uday Bhaskar, director general of B Pharmexcil, a pharma export promotion body under the Department of Commerce, said that there is no policy for other countries regarding covid-19 vaccine exports, it can be assumed that the center can ensure that vaccine manufacturers Domestic requirements are met before being allowed to export.

We do not know how much will be exported from India.

the Indian government has the final say in this regard said Bhaskar. Director of Public Health, Telangana G. Srinivas Rao, said that although the companies are located here, the state would not get preference in vaccine allocation as it would be decided by the Center .

Prime Minister Narendra Modi visited a facility in bharat Biotechat Genome Valley here on November 28 and reviewed the progress of covaxin, the vaccine candidate for covid-19.

The state has no role in vaccine allocation. It will be decided by the Center. The official said that they will devise a method for allocating the number of doses and the states will get accordingly.

It is being developed by the company in collaboration with the Indian Council of Medical Research and the National Institute of Virology and is now under phase-3 trials.

In addition to covaxin, BB is also in the process of coming up with a vaccine that will be intranasal.

Biological E Ltd has entered into an agreement with Janssen Pharmaceutica NV, part of pharma head Johnson & Johnson, to enhance production capabilities to manufacture the covid-19 vaccine candidate currently in Phase 1/2 of clinical trials.

The International Finance Corporation, a member of the World Bank Group, recently announced a loan of 30 million USD (about 220 crore rupees) to BE to support its expansion of low-cost, generic for regular immunization of children.

Aurobindo Pharma hopes to commercialize its vaccine manufacturing facility in Hyderabad by April-May next year and is investing around Rs 275 crore on the facility, using vaccines to treat various viral diseases including covid-19 will be made to produce.

Aurobindo will undertake clinical development and commercialization of vaccine.

A top official of CSIR-Center for Cellular and Molecular Biology had earlier said that three CSIR labs CCMB-Hyderabad, Institute of Medical Technology, Chandigarh and Indian Institute of Chemical Biology Kolkata are developing vaccine candidates using various technology platforms.

Dr.Reddys Laboratories Ltd and Russian Direct Investment Fund (RDIF) have already stated that they have started an adaptive phase 2/3 clinical trial for Sputnik V vaccine in India after obtaining the necessary clearance from Central Drugs Laboratory, Kasauli in Himachal.

The company has entered into an exclusive licensing agreement with covaxx, the company that makes UB-612, to develop, commercialize and manufacture UB-612 to fight covid-19 for India and the United Nations Children’s Fund. (UNICEF) is the agency.

In September 2020, Dr. Reddy’s and RDIF partnered with clinical trials of the Sputnik V vaccine and the rights to distribute the first 100 million doses in India.

Pharma leading hetero has also produced more than 100 million doses of Sputnik V per year in association with RDIF.

City-based firms were also instrumental in providing bulk drugs and formulations for some of the drugs prescribed for covid like Remedisvir and Favipiravir.

Leave a Reply

Your email address will not be published. Required fields are marked *